Addressing Loss of Exclusivity in Pharma

Bristol Myers Squibb’s latest third-quarter report highlighted an impressive 8% revenue growth, driven primarily by their diversified drug portfolio and strategic market positioning. This resilience underscores the evolving challenges in the pharmaceutical landscape, especially as major players confront the inevitable impact of loss of exclusivity (LoE) on key products. With blockbuster drugs eventually losing their exclusive patent protection, pharmaceutical companies face significant revenue erosion when generic and biosimilar competition enters the market.

The Challenge of LoE in the Pharma Sector

For an industry built on high stakes and extensive R&D investments, the end of a drug’s exclusivity can translate into billions in lost revenue. The task of offsetting these losses while maintaining sustainable growth and innovation is complex, requiring robust strategies and new approaches to commercialisation. This is where AI and advanced technology step in, providing the insights and capabilities necessary to navigate the post-LoE period with agility and foresight.

How Vamstar’s AI Tools Provide a Competitive Edge

Vamstar’s AI-driven solutions offer pharmaceutical companies a unique advantage by turning post-LoE challenges into opportunities. Here’s how:

1. Predictive Market Analytics: Vamstar’s advanced AI models can forecast market trends, competitor behaviours, and potential pricing shifts, allowing Pharma companies to adapt their strategies in anticipation of changes brought on by generic competition.
2. Intelligent Procurement and Tender Management: As companies shift their focus to new products and markets, Vamstar’s AI capabilities streamline the process of identifying and securing tenders and procurement opportunities globally. This facilitates the rapid commercialisation of next-generation therapies to offset revenue losses.
3. Portfolio Optimisation and R&D Prioritisation: By leveraging machine learning algorithms, Vamstar’s tools can analyse data across therapeutic areas, helping companies make informed decisions on which drugs to prioritise in their pipelines. This strategic focus accelerates time-to-market for high-potential candidates, ensuring a stronger post-LoE pipeline.